Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3

References

• Abe T, Kakyo M, Tokui T, et al. (1999). Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274:17159–63
   PubMed Web of Science ®Google Scholar
• Abe T, Suzuki T, Unno M, et al. (2002). Thyroid hormone transporters: recent advances. Trends Endocrinol Metab 13:215–20
   PubMed Web of Science ®Google Scholar
• Baselga J, Rischin D, Ranson M, et al. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292–302
   PubMed Web of Science ®Google Scholar
• Fenner KS, Jones HM, Ullah M, et al. (2012). The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica 42:28–45
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Gui C. (2008). Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38:778–801
   PubMed Web of Science ®Google Scholar
• Herbst RS, Maddox AM, Rothenberg ML, et al. (2002). Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20:3815–25
   PubMed Web of Science ®Google Scholar
• Hu S, Franke RM, Filipski KK, et al. (2008). Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14:3141–8
   PubMed Web of Science ®Google Scholar
• Keisner SV, Shah SR. (2011). Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71:443–54
   PubMed Web of Science ®Google Scholar
• Khurana V, Minocha M, Pal D, et al. (2014). Inhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitors. Drug Metabol Drug Interact 29:249–59
   PubMedGoogle Scholar
• Kindla J, Müller F, Mieth M, et al. (2011). Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos 39:1047–53
   PubMed Web of Science ®Google Scholar
• König J, Cui Y, Nies AT, et al. (2000). A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 278:G156–64
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al. (2008). Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022–8
   PubMed Web of Science ®Google Scholar
• McKillop D, Hutchison M, Partridge EA, et al. (2004). Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 34:917–34
   PubMed Web of Science ®Google Scholar
• Miura M. (2015). Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia. Biol Pharm Bull 38:645–54
   PubMed Web of Science ®Google Scholar
• Murakami T, Nakanishi M, Yoshimori T, et al. (2003). Separate assessment of intestinal and hepatic first-pass effects using a rat model with double cannulation of the portal and jugular veins. Drug Metab Pharmacokinet 18:252–60
   PubMedGoogle Scholar
• Nakagawa K, Tamura T, Negoro S, et al. (2003). Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14:922–30
   PubMed Web of Science ®Google Scholar
• Ogura J, Koizumi T, Segawa M, et al. (2014). Quercetin-3-rhamnoglucoside (rutin) stimulates transport of organic anion compounds mediated by organic anion transporting polypeptide 2B1. Biopharm Drug Dispos 35:173–82
   PubMed Web of Science ®Google Scholar
• Polli JW, Humphreys JE, Harmon KA, et al. (2008). The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36:695–701
   PubMed Web of Science ®Google Scholar
• Ranson M, Hammond LA, Ferry D, et al (2002). ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20:2240–50
   PubMed Web of Science ®Google Scholar
• Sato T, Yamaguchi H, Kogawa T, et al. (2014). Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug–uremic toxin interactions in the liver. J Pharm Pharm Sci 17:475–84
   PubMed Web of Science ®Google Scholar
• Sawai Y, Yamaoka K, Ito T, et al. (1997). Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. Biol Pharm Bull 20:1313–6
   PubMed Web of Science ®Google Scholar
• Tang SC, Nguyen LN, Sparidans RW, et al. (2014). Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 134:1484–94
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Kobayashi M, Okada M, et al. (2008). Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 260:163–9
   PubMed Web of Science ®Google Scholar
• Yamaguchi H, Takeuchi T, Okada M, et al. (2011). Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes. Biol Pharm Bull 34:389–95
   PubMed Web of Science ®Google Scholar
• Yamakawa Y, Hamada A, Shuto T, et al. (2011). Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin Pharmacol Ther 90:157–63
   PubMed Web of Science ®Google Scholar
• Yeung CK, Shen DD, Thummel KE, et al. (2014). Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 85:522–8
   PubMed Web of Science ®Google Scholar
• Zhou WJ, Zhang X, Cheng C, et al. (2012). Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein. Br J Pharmacol 166:1669–83
   PubMed Web of Science ®Google Scholar
• Zimmerman EI, Hu S, Roberts JL, et al. (2013). Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res 19:1458–66
   PubMed Web of Science ®Google Scholar